Investing Ideas
/
Swiss Pharmaceuticals & Biotech Undervalued based on future growth

Swiss Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

Basilea Pharmaceutica

Market Cap: CHF 665.0m

A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

BSLN

CHF 54.10

-1.8%

35.9%